Clinical References

Cumulative Sales Data. April 2018.

Danese S, et al. Aliment PharmacolTher. 2011. 33:857-69.

Gastroenterol Rep. 2015. 3(1):63-68.

FDA. CBER approval letter, infliximab [online]. 1998 [viewed September 2018].
Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/inflcen082498L.htm

[online]. 2005 [viewed: December 2017].
Available from: https://www.medscape.com/viewarticle/513282

RemicadeScientific Discussion. 2006.

[online]. 2007 [viewed: December 2017].
Available from: https://www.eurekalert.org/pub_releases/2007-11/ci-rbf110607.php

[online]. 2017 [viewed: September 2018].
Available from: www.remicade.com

J Crohns Colitis. 2017. 11(1):26-34.

Scand J Gastroenterol. 2004. 39:1017–1020.

Gastroenterology. 2011. 140:1817–1826.

Clin Gastroenterol Hepatol. 2014. 12:1887–1893.

Lancet 2017. 389:2304–2316

Ann Rheum Dis. 2013. 72:1613–1620

Ann Rheum Dis. 2013. 72:1605–1612

Ann Rheum Dis. 2017. 76:355–363

Ann Rheum Dis. 2017. 76:346–354.

Inflamm Bowel Dis. 2017. 23:233–243.

ECCO 2017. Abstract P331. J Crohns Colitis 2017; 11/Supp 1.

Expert Rev Clin Immunol. 2017. 13:653–666.

Worldwide Experience with Biosimilar Development. MAbs. 2011. 3(2):209-217.

Health Canada/BIOTECanada Summit on Regulatory and Clinical Topics Related to Subsequent Entry Biologics (biosimilars). Biologicals. 2012. 40(6):517-527.

The Advent of Biosimilar Therapies in Rheumatology—“O Brave New World.” Nat Rev Rheumatol. 2012. 8(7):430-436.

Pharmacoeconomics of Cancer Therapies: Considerations with the Introduction of Biosimilars. Semin Oncol. 2014. 41(suppl 3):S13-S20.

Biopharmaceuticals and Biosimilars in Psoriasis: What the Dermatologist Needs to Know. J Am Acad Dermatol. 2012. 66(2):317-322.

Delivering on the Potential of Biosimilar Medicines, The Role of Functioning Competitive Markets. 2016. [viewed: May 2018].
Available from: http://medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilars-Report-March-2016-FINAL.pdf
 

ArthRes Ther. 2016. 18:82. DOI 10.1186/s13075-016-0981-6.

Arth Res Ther. 2016. 18:25.DOI 10.1186/s13075-016-0930-4.

Gastroenterology. 2012. 142:46-54.

J Crohn’s Colitis. 2013. 7:322-37.

Abstract 101, AOCC 2017

Abstract DOP061. Ecco 2017. J Crohns Colitis. 2017. I I/Supp I.

Abstract LB04, UEGW 2017. United European Gastroenterol J. 2017. 5: 1139-40

Lancet 2017. 389:2304–2316. Supplementary Appendix.

.J Crohns Colitis. 2016. 10(2):133-40.

J Crohns Colitis 2017; 11/Supp 1 [Alfonso J, et al. Ametzazurra A, et al. P503. Choe YH, et al. P500. Curdia Goncalves T, et al. P472. Fiorino G, et al. P605. Gecse KB, et al. P331. Gonzalez A., et al. P508. Han S, et al. P582. Juan G, et al. P632. Kaniewska M, et al. P425. Kolar M, et al. P532. Lovasz, et al. P592. Molnar, et al. P675. Mortier K, et al. P333. Eberl A, et al. P639. Huoponen S, et al. P685. Smits L, et al. P663. Strik A, et al. P665. Gompertz M, et al. P679. Guerrero Puente LN, et al. P545. Rodriguez Glez GE, et al. P629. St. Clair Jones A, et al. P527. Plevris N, et al. P586. Nugent S, et al. P430. Soret PA, et al. P471. Choe YH, et al. P487. Kamg B, et al. P542. Sladek M, et al. P661. Fiorino G, et al. P633.]

J Crohns Colitis 2016. 10/Supp 1 [Bortilk M, et al. P495. Carvalho L, et al. P327. Hamanaka S, et al. P329. Kaniewska M, Rydzewska G. P645. Zagorowicz E, et al. P513. Kolar M, et al. DOP032. Diaz Hernandez L, et al. P449. Guerra Veloz MF, et al. P452. Guerra Veloz MF, et al. P600. Muhammed R, et al. P382. Sieczkowska J, et al. P530. Turk N, et al. P577.]

J Crohns Colitis. 2016. 10:1273-78.

Gastroenterol Hepatol. 2016. 70:27-36.

Expert Rev Gastroenterol Hepatol. 2015. 9(S1):S45-52.

ScandJ Gastroenterol. 2016. 51:1062-68.

Gut 2016;7/Supp1 [Ala K, et al. PTU-059. Bennett KJ, et al. PWE-017. Chung L, et al. OC-038. RahmanyS, et al. PTU-073.]

J Crohns Colitis. 2017. 11(6):690-6.

J Crohns Colitis. 2016. 10:1287-93.

CurrMed Chem. 2016. 23:1-10.

Saving money in the European healhtcare systems with  biosimilars. GaBi Journal. 2012. 1(3-4):120-126.

Abstract P530. J Crohns Colitis. 2016. 10/Supp 1.

Abstract P487. J Crohns Colitis. 2017. 11/Supp 1.

Abstract P661. J Crohns Colitis.  2017. 11/Supp 1.

Inflamm Bowel Dis. 2012. 18:349–358.

Gastroenterol Hepatol 2016. 12:308–315.

Pharmacol Ther.  2008. 117:244–279.

J Crohns Colitis. 2012. 6:143–153

Gastroenterology. 2014. 147:1296–1307.

J Crohns Colitis. 2013. 7:736–743.

Gut. 2014. 63:1258–1264.

Clin Trans Gastroenterol. 2016. 7:e135

J Crohns Colitis. 2017. 11:S4, ECCO abstract OP003.

Gut. 2007. 56:1226–1231.

Gut. 2017. epub April 274

Gastroenterology. 2015. 148:1320–1329.

Gut. 2014. 63:919–927.

Journal of Market Access & Health Policy. 2015. 3:292–29.

Aliment Pharmacol Ther. 2016. 43:30-51.

Gastroenterol Hepatol. 2007. 9:521–527

J Crohns Colitis 2017. 11:S4, ECCO abstract OP006.

Aliment Pharmacol Ther.  2013. 38:447–459.

Scand J Gastroenterol. 2009. 44:774–781.

Expert Opin Drug Saf. 2017. 16:303–317.

J Crohns Colitis.  2015. 9:26–32.

Scand J Gastroenterol. 1999. 34:50–54.

Inflamm Bowel Dis. 2014. 20:1407–1415.

 

 

 

PP-IFA-GBR-0331. February 2019